

Brian Lau

Associate



blau@cooley.com

Capital Markets
Asia

+852 3758 1247

Hong Kong

Brian focuses his practice on initial public offerings on the Hong Kong Stock Exchange, as well as on Hong Kong listing rules and securities regulations compliance advisory work.

Brian is fluent in English, Mandarin and Cantonese.

Representative matters:

Primary Offering

- Joint sponsors **Morgan Stanley, CICC and GF Securities** as joint sponsors in the HK\$2.277 billion IPO and listing of **Insilico Medicine**, a global, clinical-stage, generative artificial intelligence (AI)-driven biotech responsible for advancing the first generative AI-discovered and designed drug to human clinical trials
- **WeRide**, a global leader in autonomous driving technology, in its HK\$2.91 billion IPO on HKEX
- **Butong Group**, a company that specializes in the design and sale of nursery products, on its HK\$781.84 million IPO
- **Leads Biolabs**, a clinical-stage biotechnology company, on its HK\$1.29 billion IPO and listing on HKEX
- Joint sponsors and underwriters **CICC, Citigroup and Merrill Lynch (Asia Pacific)** on HK\$198 million IPO and listing of **Fenbi**, a leading online education company on HKEX
- Joint sponsors and underwriters **Citi and Huatai International** on HK\$210 million IPO and listing of **Cryofocus Medtech**, a leading medical device company on HKEX
- **TI Cloud**, a cloud-native customer contact solution provider, on its HK\$559.4 million (US\$71.7 million) IPO and listing on HKEX

Listed Issuers' Compliance

- **Leads Biolabs** on its compliance obligations as a listed issuer on HKEX
- **Jacobio Pharmaceuticals** on its compliance obligations as a listed issuer on HKEX
- **Hilong Holding** on its compliance obligations as a listed issuer on HKEX
- **TI Cloud** on its compliance obligations as a listed issuer on HKEX
- **GOGOX** on its compliance obligations as a listed issuer on HKEX

Others

- **Jacobio Pharmaceuticals'** placement of existing shares and top-up subscription of new shares under general mandate totaling HK\$160.4 million
- **ImmuneOnco** on its HK\$234 million follow-on offering
- **MindWorks Capital**, a Hong Kong-headquartered next-generation venture capital manager, on the closing of its fourth Pan-Asia venture capital fund, MindWorks Ventures Fund IV

Representative Publications

- "[Chambers Global Practice Guide: Blockchain 2025 \(Hong Kong SAR, China\)](#)," Chambers and Partners, June 2025
- [Hong Kong Private Fund Offering Playbook](#), September 2024
- Contributed to the launch of the Hong Kong Venture Capital and Private Equity Association's (HKVCA) set of model legal documents

Education

The Chinese University of Hong Kong Postgraduate Certificate in Laws, 2017

The Chinese University of Hong Kong LLM, International Economic Law, 2016

The University of Manchester LLB, 2015

Admissions & Credentials

Solicitor of Hong Kong

New York